An Open-label, Single-arm, Multi-centre, Phase II Study of Oral Lapatinib in Combination With Paclitaxel as First-line Treatment for ErbB2-amplified Metastatic Breast Cancer Patients
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2015
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Aug 2013 Planned end date changed from 1 Feb 2008 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 15 Oct 2008 Actual start date changed from Feb 2006 to May 2006 as reported by ClinicalTrials.gov.